Effect of an antimicrobial stewardship intervention on outcomes for patients with Clostridium difficile infection

American Journal of Infection Control

Volumn 44, Issue 12, 2016, Pages 1539-1543

  Welch, Hanna K ^a   Nagel, Jerod L ^b   Patel, Twisha S ^b   Gandhi, Tejal N ^c   Chen, Benrong ^b   De Leon, John ^a   Chenoweth, Carol E ^c   Washer, Laraine L ^b,c   Rao, Krishna ^c,d   Eschenauer, Gregory A ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Colitis; Oral vancomycin; Proton pump inhibitors

Indexed keywords

METRONIDAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP PROGRAM; ARTICLE; BACTERIAL PERITONITIS; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; FEMALE; HEALTH PROGRAM; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; ILEOSTOMY; ILEUS; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEGACOLON; MORTALITY; OUTCOME ASSESSMENT; QUASI EXPERIMENTAL STUDY; RECURRENT INFECTION; ADOLESCENT; CLOSTRIDIUM INFECTION; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG UTILIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; STANDARDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG THERAPY; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84999018325     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2016.05.027     Document Type: Article

References (31)

1. 1 Lessa, F.C., Mu, Y., Bamberg, W.M., Beldavs, Z.G., Dumyati, G.K., Dunn, J.R., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 825–834, 10.1056/NEJMoa1408913.
2. 2 Magill, S.S., Edwards, J.R., Bamberg, W., Beldavs, Z.G., Dumyati, G., Kainer, M.A., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370 (2014), 1198–1208, 10.1056/NEJMoa1306801.
3. 3 Hensgens, M.P., Goorhuis, A., Dekkers, O.M., van Benthem, B.H., Kuijper, E.J., All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis 56 (2013), 1108–1116, 10.1093/cid/cis1209.
4. 4 Cohen, S.H., Gerding, D.N., Johnson, S., Kelly, C.P., Loo, V.G., McDonald, L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31 (2010), 431–455, 10.1086/651706.
5. 5 Feazel, L.M., Malhotra, A., Perencevich, E.N., Kaboli, P., Diekema, D.J., Schweizer, M.L., Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 69 (2014), 1748–1754, 10.1093/jac/dku046.
6. 6 Huang, A.M., Newton, D., Kunapuli, A., Gandhi, T.N., Washer, L.L., Isip, J., et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 57 (2013), 1237–1245, 10.1093/cid/cit498.
7. 7 Nagel, J.L., Huang, A.M., Kunapuli, A., Gandhi, T.N., Washer, L.L., Lassiter, J., et al. Impact of antimicrobial stewardship intervention on coagulase-negative Staphylococcus blood cultures in conjunction with rapid diagnostic testing. J Clin Microbiol 52 (2014), 2849–2854, 10.1128/JCM.00682-14.
8. 8 Nguyen, C.T., Gandhi, T., Chenoweth, C., Lassiter, J., Dela Pena, J., Eschenauer, G., et al. Impact of an antimicrobial stewardship-led intervention for Staphylococcus aureus bacteraemia: a quasi-experimental study. J Antimicrob Chemother 70 (2015), 3390–3396, 10.1093/jac/dkv256.
9. 9 Pogue, J.M., Mynatt, R.P., Marchaim, D., Zhao, J.J., Barr, V.O., Moshos, J., et al. Automated alerts coupled with antimicrobial stewardship intervention lead to decreases in length of stay in patients with gram-negative bacteremia. Infect Control Hosp Epidemiol 35 (2014), 132–138, 10.1086/674849.
10. 10 Barbut, F., Surgers, L., Eckert, C., Visseaux, B., Cuingnet, M., Mesquita, C., et al. Does a rapid diagnosis of Clostridium difficile infection impact on quality of patient management?. Clin Microbiol Infect 20 (2014), 136–144, 10.1111/1469-0691.12221.
11. 11 Modena, S., Gollamudi, S., Friedenberg, F., Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. J Clin Gastroenterol 40 (2006), 49–54.
12. 12 Pop-Vicas, A., Shaban, E., Letourneau, C., Pechie, A., Empirical antimicrobial prescriptions in patients with Clostridium difficile infection at hospital admission and impact on clinical outcome. Infect Control Hosp Epidemiol 33 (2012), 1101–1106, 10.1086/668015.
13. 13 Linsky, A., Gupta, K., Lawler, E.V., Fonda, J.R., Hermos, J.A., Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 170 (2010), 772–778, 10.1001/archinternmed.2010.73.
14. 14 Neal, M.D., Alverdy, J.C., Hall, D.E., Simmons, R.L., Zuckerbraun, B.S., Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 254 (2011), 423–429, 10.1097/SLA.0b013e31822ade48.
15. 15 Dubberke, E.R., Carling, P., Carrico, R., Donskey, C.J., Loo, V.G., McDonald, L.C., et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 35:Suppl 2 (2014), S48–65, 10.1086/676023.
16. 16 Brumley, P.E., Malani, A.N., Kabara, J.J., Pisani, J., Collins, C.D., Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection. J Antimicrob Chemother 71 (2016), 836–840, 10.1093/jac/dkv404.
17. 17 Jardin, C.G., Palmer, H.R., Shah, D.N., Le, F., Beyda, N.D., Jiang, Z., et al. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect 85 (2013), 28–32, 10.1016/j.jhin.2013.04.017.
18. 18 Jury, L.A., Tomas, M., Kundrapu, S., Sitzlar, B., Donskey, C.J., A Clostridium difficile infection (CDI) stewardship initiative improves adherence to practice guidelines for management of CDI. Infect Control Hosp Epidemiol 34 (2013), 1222–1224, 10.1086/673459.
19. 19 Muto, C.A., Blank, M.K., Marsh, J.W., Vergis, E.N., O'Leary, M.M., Shutt, K.A., et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 45 (2007), 1266–1273, 10.1086/522654.
20. 20 Yeung, S.S., Yeung, J.K., Lau, T.T., Forrester, L.A., Steiner, T.S., Bowie, W.R., et al. Evaluation of a Clostridium difficile infection management policy with clinical pharmacy and medical microbiology involvement at a major Canadian teaching hospital. J Clin Pharm Ther 40 (2015), 655–660, 10.1111/jcpt.12329.
21. 21 Bagdasarian, N., Rao, K., Malani, P.N., Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 313 (2015), 398–408, 10.1001/jama.2014.17103.
22. 22 Surawicz, C.M., Brandt, L.J., Binion, D.G., Ananthakrishnan, A.N., Curry, S.R., Gilligan, P.H., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498, 10.1038/ajg.2013.4.
23. 23 Zar, F.A., Bakkanagari, S.R., Moorthi, K.M., Davis, M.B., A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007), 302–307, 10.1086/519265.
24. 24 McDonald, L.C., Coignard, B., Dubberke, E., Song, X., Horan, T., Kutty, P.K., et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28 (2007), 140–145, 10.1086/511798.
25. 25 Hensgens, M.P., Dekkers, O.M., Goorhuis, A., LeCessie, S., Kuijper, E.J., Predicting a complicated course of Clostridium difficile infection at the bedside. Clin Microbiol Infect 20 (2014), O301–8, 10.1111/1469-0691.12391.
26. 26 Morrison, R.H., Hall, N.S., Said, M., Rice, T., Groff, H., Brodine, S.K., et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 53 (2011), 1173–1178, 10.1093/cid/cir668.
27. 27 Rao, K., Micic, D., Natarajan, M., Winters, S., Kiel, M.J., Walk, S.T., et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis 61 (2015), 233–241, 10.1093/cid/civ254.
28. 28 Evans, M.E., Kralovic, S.M., Simbartl, L.A., Whitlock, J.L., Jain, R., Roselle, G.A., Complications of hospital-onset healthcare facility-associated Clostridium difficile infections among veterans. Infect Control Hosp Epidemiol 37 (2016), 717–719, 10.1017/ice.2016.33.
29. 29 Johnson, S., Louie, T.J., Gerding, D.N., Cornely, O.A., Chasan-Taber, S., Fitts, D., et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 59 (2014), 345–354, 10.1093/cid/ciu313.
30. 30 Cornely, O.A., Crook, D.W., Esposito, R., Poirier, A., Somero, M.S., Weiss, K., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12 (2012), 281–289, 10.1016/S1473-3099(11)70374-7.
31. 31 Louie, T.J., Miller, M.A., Mullane, K.M., Weiss, K., Lentnek, A., Golan, Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364 (2011), 422–431, 10.1056/NEJMoa0910812.